1. Antiplatelet Therapy for Atherothrombotic Disease: An Update for the Primary Care Physician 
George E. Kikano, MD, Marie T. Brown, MD 
Mayo Clinic Proceedings 
Volume 82, Issue 5, Pages (May 2007)
DOI: /
Copyright © 2007 Mayo Foundation for Medical Education and Research Terms and Conditions

2. FIGURE 1
Direct comparisons of proportional effects of different antiplatelet regimens on vascular events in high-risk patients. Only meta-analyses involving a total of 500 or more high-risk patients are shown. GP = glycoprotein.
*Includes one trial comparing 1400 mg/d vs 350 mg/d of aspirin and another (excluding those with acute stroke) comparing 1000 mg/d vs 300 mg/d among patients who were also given dipyridamole.
†Includes 2 trials comparing mg/d of aspirin vs <75 mg/d of aspirin and 1 trial of mg/d of aspirin vs <75 mg/d of aspirin.
‡Includes cilostazol, sulotroban, Trapidil, E5510, eptifibatide, and GR32191B. Stratified ratio of odds of an event in the regimen 1 group to that in the regimen 2 group is plotted for each group of trials (black square) along with its 99% confidence interval (horizontal line). Meta-analysis of results for all trials for a particular comparison (and 95% confidence interval) is represented by an open diamond.
From BMJ,35 with permission.
Mayo Clinic Proceedings  , DOI: ( / )
Copyright © 2007 Mayo Foundation for Medical Education and Research Terms and Conditions

3. FIGURE 2
Odds ratios and 95% confidence intervals (CIs) for the effect of active treatment vs placebo on the principal end points of stroke, stroke or death, and death in the European Stroke Protection 2 study. Significant relative risk reductions for stroke were observed for aspirin (ASA) vs placebo (P=.013), dipyridamole (DP) vs placebo (P=.039), and ASA-DP vs placebo (P<.001); relative risk reductions with ASA-DP were significantly greater than for ASA and DP alone (P=.006 and P=.002, respectively). Compared with placebo, relative risk reductions for stroke or death were statistically significant for ASA (P=.016), DP (P=.015), and ASA-DP (P<.001); the combination was not significantly more effective than either ASA or DP monotherapy. None of the study medications significantly reduced the risk of death. From J Neurol Sci,36 with permission.
Mayo Clinic Proceedings  , DOI: ( / )
Copyright © 2007 Mayo Foundation for Medical Education and Research Terms and Conditions

4. FIGURE 3
Benefits of clopidogrel over aspirin (ASA) in patients with previous acute events expressed as relative risk reduction. Shown are both composite end points compared with the entire Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE) trial population. IS = ischemic stroke; MI = myocardial infarction; TIA = transient ischemic attack. From Stroke,40 with permission.
Mayo Clinic Proceedings  , DOI: ( / )
Copyright © 2007 Mayo Foundation for Medical Education and Research Terms and Conditions